Nucleic Acid Pathogen Testing - (0530) — MM 0530 | CIGNA Coverage Update

TL;DR: Cigna Healthcare modified MM 0530, its nucleic acid pathogen testing coverage policy, with an effective date of February 14, 2026. If your team bills any of the 72 CPT codes covered under this policy — from STD panels to respiratory pathogen arrays to CNS pathogen detection — review your documentation criteria now.

The Cigna nucleic acid infectious pathogen testing coverage policy (MM 0530 Cigna system) governs a wide range of DNA and RNA-based diagnostic tests across STDs, respiratory infections, gastrointestinal pathogens, wound infections, vaginal infections, and central nervous system pathogens. This modification touches codes including 87491 (Chlamydia trachomatis, amplified probe), 87591 (Neisseria gonorrhoeae, amplified probe), 87624 (HPV high-risk types), 87631 and 87633 (respiratory virus panels), and newer proprietary panel codes like 0321U, 0369U, and 0480U. If your lab or practice bills any of these codes to Cigna, this update requires your attention before claims go out the door.

Quick-Reference Table

Cigna Nucleic Acid Pathogen Testing Coverage Criteria and Medical Necessity Requirements 2026

The Cigna nucleic acid pathogen testing coverage policy classifies all 72 CPT codes under a single coverage position: Considered Medically Necessary when criteria in the applicable Coverage Policy are met. There is no blanket approval here. Every test requires documented clinical justification tied to the specific criteria Cigna has established for each pathogen type and clinical scenario.

The policy covers testing for DNA and RNA of pathogens that cause STDs, skin and nail infections, pulmonary infections, gastrointestinal infections, CNS infections, and genitourinary tract infections. Panel testing — where a single order detects multiple pathogens simultaneously — falls under the same medical necessity framework. That matters for high-code-count panels like 0369U (31 gastrointestinal pathogens) and 0480U (CSF metagenomic sequencing), where documentation must justify the panel rather than a targeted single-pathogen test.

Two important scope boundaries: this policy does not cover inpatient testing. Any nucleic acid pathogen testing billed from an inpatient level of care is outside MM 0530 entirely. Separately, COVID-19-only testing (SARS-CoV-2 single-virus tests) falls under Cigna policy 0557, not MM 0530. However, combination codes like 87636 and 87637 — which detect SARS-CoV-2 alongside influenza A, influenza B, and RSV — do fall under MM 0530.

Prior authorization requirements are not explicitly enumerated code-by-code in the summary data, but the medical necessity criteria framework means your documentation must be airtight before the claim goes out. All 72 codes require documented medical necessity per MM 0530 criteria. If you're billing 0152U (metagenomic next-generation sequencing) or 0323U (CNS pathogen metagenomic sequencing), make sure the ordering provider's documentation clearly shows why a targeted test was insufficient.

The real issue here is the breadth of this policy. Seventy-two CPT codes across this many clinical settings means nearly every lab-heavy specialty has some exposure to MM 0530. This isn't a narrow STD-panel update. This touches respiratory medicine, neurology, wound care, and GI — any department that orders nucleic acid-based diagnostics for Cigna-covered patients.

Cigna Nucleic Acid Pathogen Testing Exclusions and Non-Covered Indications

The policy summary does not list explicit experimental or investigational designations for individual codes. All 72 CPT codes carry the same conditional coverage label. That means denial risk doesn't come from a code being categorically excluded — it comes from failing the medical necessity criteria on a case-by-case basis.

What does function as a de facto exclusion: inpatient testing and standalone COVID-19 testing. Standalone SARS-CoV-2 single-virus tests fall under policy 0557, not MM 0530. Any code billed as a COVID-only test at the inpatient level is outside this policy's scope on both grounds. Your billing team needs to know where those boundaries are before claims go out.

Coverage Indications at a Glance

Cigna Nucleic Acid Pathogen Testing Billing Guidelines and Action Items 2026

The scope of this policy update demands a structured response from your billing and lab teams. Here's what to do.

CPT, HCPCS, and ICD-10 Codes for Nucleic Acid Pathogen Testing Under MM 0530

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full MM 0530 ICD-10 code set includes 453 diagnosis codes spanning STDs, respiratory infections, gastrointestinal infections, CNS infections, genitourinary infections, skin and nail infections, and fungal conditions. Review the full code list at the Cigna MM 0530 policy source.